ZYNE - Zynerba Pharmaceuticals, Inc.
| Previous Close | 10.62 |
| Open | 10.67 |
| Bid | 11.11 x 1400 |
| Ask | 11.34 x 900 |
| Day's Range | 10.67 - 11.34 |
| 52 Week Range | 2.75 - 16.47 |
| Volume | 674,076 |
| Avg. Volume | 1,642,969 |
| Market Cap | 259.818M |
| Beta (3Y Monthly) | 4.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.75 |
- TipRanks
3 Healthcare Stocks to Fight Off the Market Flu
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, respectively. From an economic perspective, the unemployment levels and interest rates have remained low, which helped boost share prices. That being said, the market isn’t immune to the recent dramas that have unfolded. The ongoing trade war with China and weak global growth have raised red flags among investors that a recession could be on the way, with those fears causing widespread volatility.However, analysts are telling investors not to panic. Wall Street analysts believe that healthcare stocks still represent compelling investment opportunities amid economic uncertainty.Using TipRanks powerful stock screener, we set out to pinpoint three stocks that command the support of the Street. You can customize the screener settings to match your investment strategy. In this case, we selected filters for healthcare stocks with a “strong buy” consensus ratings. We also specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target.Now let’s delve into these three top healthcare stocks and see if they really have what it takes to fight off the market flu: Novavax Inc. (NVAX)The first healthcare company on our list develops vaccines that target respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV).Novavax has riled up Wall Street last week with enticing Phase III ResVax trial results. The data presented at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) on August 12 showed that the company's ResVax vaccine was able to protect infants one year after birth from all causes of pneumonia, including RSV associated pneumonia. It also highlighted the fact that protecting infants from the RSV infection can protect infants from contracting an infection from other microbes.Investors have more reasons to be excited about the vaccine maker. On August 5, NVAX reached an agreement with the FDA on its Phase 3 trial design for Nanoflu, its seasonal influenza vaccine for adults 65 years and older. The company also partnered with Catalent Biologics (CTLT) back in June, allowing CTLT to expand its gene therapy footprint with the acquisition of Novavax’s manufacturing assets and capabilities.B.Riley FBR analyst George Zavoico remains bullish on NVAX with a Buy rating, and his $35 price target, which seems like wishful thinking, may get another boost: “Based on these new results and other recent events, we place our price target for Novavax under review as we update our financial model of the company.” (To watch Zavoico's track record, click here)"We do not believe these new, positive results will lead the FDA to reconsider its decision to require another Phase III trial of ResVax by maternal immunization before considering a BLA filing. While we still forecast that the European Medicines Agency (EMA) is likely to agree with the FDA on this point, we would not be surprised if, due partly to these new results, the EMA may decide to allow Novavax to file a marketing authorization application (MAA) for ResVax while also requiring a post-marketing efficacy trial to confirm the results. A decision is expected this fall," Zavoico opined.All in all, the rest of the Street mirrors the analysts’ bullish sentiment. NVAX has a ‘Strong Buy’ analyst consensus and a $29.88 average price target, implying ~281% upside potential from current levels. (See NVAX’s price targets and analyst ratings on TipRanks) Amarin Corporation (AMRN)It’s no secret that Wall Street analysts like Amarin stock. It has a ‘Strong Buy’ analyst consensus and a ~$32 average price target, suggesting over 100% upside potential from current levels. (See AMRN’s price targets and analyst ratings on TipRanks)Investors were caught by surprise recently after Amarin announced the FDA’s notice of plans to hold an advisory committee (AdCom) on the sNDA for its Vascepa drug.4-star Roth Capital analyst Yasmeen Rahimi argues that the AdCom might work in AMRN’s favor.While the news comes as a shock given how close AMRN is to its September 28 priority-review PDUFA for Vascepa, management stated in May that they believed an AdCom was likely as they are seeking a Vascepa label extension. As such, the AdCom gives AMRN a platform to defend its label extension as well as highlight Vascepa’s ability to reduce cardiovascular related events and deaths, its superior safety and its support from the medical community.“AdCom allows for Vascepa discussion in a public forum, increasing awareness and transparency on key issues, and puts all this info just a click away for potential future Vascepa-prescribers to find and digest,” Rahimi opined, as she reiterates her Buy rating and $31 price target on Amarin stock."In totality, we believe AMRN is primed to make a strong case to the FDA and can turn this AdCom into a highlight reel of the CV benefits Vascepa offers patients," the analyst concluded. (To watch Rahimi's track record, click here) Zynerba Pharmaceuticals (ZYNE)Zynerba develops innovative therapies to treat Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).Investment firm Canaccord Genuity has hosted Zynerba at its annual growth conference the day after its second quarter earnings release in which the company altered some timelines for its data readouts. Lead analyst Sumant Kulkarni believes the company is still cautiously optimistic regarding its Zygel (cannabidiol gel) in Fragile X syndrome (FXS). While its Zygel trial enrollment continues, the company hasn’t provided an end date for enrollment. ZYNE does remain confident that Zygel use in DEE treatment can deliver an adequate dose of CBD via the transdermal route.The analyst points out that an Epidiolex CBD solution for Lennox-Gastaut/Dravet syndromesits has already been released by its competitor, GW Pharmaceuticals (GWPH). Not to mention GWPH’s market cap is $5 billion versus ZYNE’s $250 million. However, Kulkarni argues that this disparity represents a unique buying opportunity.Based on all of the above factors, Kulkarni reiterates his Buy rating and $18 price target on ZYNE stock, which implies about 60% upside from current levels.Kulkarni is certainly not the first analyst with an optimistic outlook for the biotech firm, as TipRanks analytics showcasing ZYNE stock as a Strong Buy. With an average price target of $22, analysts are predicting an upside of nearly 100%. In total, the stock has received 4 'buy' ratings in the last three months. (See ZYNE’s price targets and analyst ratings on TipRanks)
- Simply Wall St.
When Can We Expect A Profit From Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)?
Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty...
- Motley Fool
Here's Why Zynerba Pharmaceuticals Lost 21.8% in July
The stock cooled off along with its cannabis-based peers.
- Zacks
Zynerba (ZYNE) Meets Earnings Estimates in Q2, Revenues Nil
Zynerba Pharmaceuticals (ZYNE) reported in-line with market expectation in the second quarter with earnings meeting estimates.
- GlobeNewswire
Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of data from the Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial. This trial evaluated ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). “Fragile X is a family diagnosis, impacting not only the diagnosed child but also the entire family unit,” said Honey Heussler, MBBS, FRACP, MRCPCH, PGCAP, DM, Associate Professor, University of Queensland and Medical Director Child Development, Children’s Health Queensland, and an investigator in the FAB-C study.
- GlobeNewswire
Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
DEVON, Pa., Aug. 06, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.
- GlobeNewswire
Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Canaccord Genuity 39th Annual Growth Conference. The presentation will take place on Wednesday August 7, 2019 at 5:00PM EDT at the InterContinental Hotel in Boston, Massachusetts. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.
- Investopedia
Top Marijuana Stocks on the NASDAQ
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
- Zacks
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
- TheStreet.com
Zynerba Pharma Looks Like Bad Medicine for Investors
Jim Cramer is wary of Zynerba Pharmaceuticals . "No. If you want this, you want GW Pharmaceuticals ," said Cramer to a caller during the Lightning Round of his "Mad Money" program on Monday. In this daily bar chart of ZYNE, below, we can see that prices quietly bottomed around $3 in late December.
- Benzinga
Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More
On Monday's “Mad Money,” Jim Cramer said he remains bearish on Range Resources Corp. (NYSE: RRC ) saying natural gas is the weakest part of the petrol chain. Cramer says although it's speculative, he is ...
- Zacks
Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $11.87, marking a +1.63% move from the previous day.
- Motley Fool
Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year
The marijuana craze has hit this clinical-stage pharmaceutical company.
- Motley Fool
5 Best Biotech Stocks of 2019 So Far
These biotech stocks have at least quadrupled in just over six months this year.
- Motley Fool
These Are the Only 15 Pot Stocks That Rose in the Second Quarter
Only around 1 in 4 marijuana stocks ended the second quarter higher.
- Simply Wall St.
Is Zynerba Pharmaceuticals's (NASDAQ:ZYNE) 102% Share Price Increase Well Justified?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
- Yahoo Finance
Why Medicare for all could 'dramatically' increase access to medical marijuana
Medicare for all may not be just a Democratic talking point as the 2020 campaign kicks into high gear. It could also “dramatically” increase access to medical marijuana, according to Nicholas Vita, CEO of cannabis company Columbia Care.
- Market Realist
Zynerba Gets Another Boost with Addition to Russell Index
Today, Zynerba Pharmaceuticals (ZYNE) announced its stock would be added to the Russell 2000 Index and the Russell 3000 Index.
- Motley Fool
The Best Marijuana Stocks in the First Half of 2019
Seven cannabis stocks doubled, and nearly two-thirds of all pot stocks ended the period higher.
- GlobeNewswire
Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the Company will be added as a member of the U.S. all-cap Russell 3000® and small-cap Russell 2000® Indexes at the conclusion of the 2019 Russell indexes annual reconstitution. The annual reconstitution will conclude and the newly reconstituted indexes will begin running at the open of the U.S. markets today, July 1, 2019. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 10, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes.
- Benzinga
Canaccord Genuity Bullish On Zynerba Ahead Of CBD Gel Trial Data
Investors continue to show interest in the medical possibilities of cannabis-derived cannabidiol, or CBD, eagerly watching Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) as it begins patient trials on a CBD-infused ...
- Zacks
Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know
Zynerba Pharmaceuticals (ZYNE) closed at $12.48 in the latest trading session, marking a -0.56% move from the prior day.
